Methods of determining acute myeloid leukemia response to...

C - Chemistry – Metallurgy – 12 – Q

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12Q 1/68 (2006.01) G01N 33/68 (2006.01) C12Q 1/48 (2006.01)

Patent

CA 2680909

A simple two gene expression assay, RASGRPI:APTX, with utility in diagnosing a population of acute myeloid leukemia (AML) patients who are more likely to respond to farbesyltransferase inhibition with tipifamib (RI15777. ZARNESTRA).

L'invention concerne un simple dosage d'expression à deux gènes, RASGRPI:APTX, ayant une utilité dans le diagnostic d'une population de patients atteints de leucémie myéloïde aiguë (AML) plus susceptibles de répondre à une inhibition de la farnésyltransférase avec du tipifamib (RI15777. ZARNESTRA).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of determining acute myeloid leukemia response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of determining acute myeloid leukemia response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining acute myeloid leukemia response to... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1373624

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.